Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Corcept Therapeutics (CORT) Receivables (2016 - 2025)

Corcept Therapeutics (CORT) has disclosed Receivables for 14 consecutive years, with $63.9 million as the latest value for Q4 2025.

  • Quarterly Receivables rose 10.0% to $63.9 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $63.9 million through Dec 2025, up 10.0% year-over-year, with the annual reading at $63.9 million for FY2025, 10.0% up from the prior year.
  • Receivables hit $63.9 million in Q4 2025 for Corcept Therapeutics, down from $73.5 million in the prior quarter.
  • In the past five years, Receivables ranged from a high of $80.0 million in Q1 2025 to a low of $23.9 million in Q1 2021.
  • Historically, Receivables has averaged $47.4 million across 5 years, with a median of $46.6 million in 2023.
  • Biggest five-year swings in Receivables: fell 14.9% in 2021 and later soared 65.22% in 2023.
  • Year by year, Receivables stood at $27.6 million in 2021, then skyrocketed by 63.1% to $45.1 million in 2022, then fell by 4.96% to $42.8 million in 2023, then skyrocketed by 35.62% to $58.1 million in 2024, then rose by 10.0% to $63.9 million in 2025.
  • Business Quant data shows Receivables for CORT at $63.9 million in Q4 2025, $73.5 million in Q3 2025, and $68.7 million in Q2 2025.